The most foundational step has been relocating the unit's decision-making authority entirely inside China. Yang stated that Nexperia China's core management, research and development, and production teams are now fully based in the country and possess "complete operational decision-making authority" . This is a structural break from the pre-crisis governance framework, under which the Dutch headquarters in Nijmegen controlled strategy for all global subsidiaries, including the factory in Dongguan, Guangdong province
.
The change carries practical weight. Nexperia's European management has acknowledged it can no longer oversee operations in China. In a May 2026 public update, Nexperia BV stated that its Chinese entities had "stopped operating within the established corporate governance framework" and were ignoring lawful instructions from global management .
The operational independence hinges on solving a supply chain crisis. After the Dutch government's intervention in October 2025, Nexperia Europe halted critical shipments of silicon wafers to the Chinese unit, disrupting production of power semiconductors used by automakers .
Wingtech's response was to build a parallel supply chain inside China as quickly as possible. As of December 2025, Nexperia China had already locked in supplies from local firms to cover its entire 2026 production of Insulated-Gate Bipolar Transistor (IGBT) power chips, according to a Reuters report that cited an internal document . The company has since formalised what it calls a "stable supply model based on multiple nodes and multiple sources" to replace the severed European links
.
According to a supply chain risk report published by ASC Global, the shift is now near-complete: Nexperia China is transitioning to 100% domestic Chinese wafers for key power products such as IGBTs and MOSFETs . The report described the governance battle as having transformed "from a boardroom dispute into a near-total operational split," with the European headquarters and Chinese subsidiary now operating "as two separate, often hostile, entities" as of April 2026
.
Independent research and development is the third pillar of Wingtech's strategy. In March 2026, Nexperia China announced what it described as a "breakthrough" in its independent manufacturing capabilities: the first small-batch production of 12-inch wafer bipolar discrete devices .
This was a deliberate signal. The achievement used only domestic equipment and suppliers, bypassing the European-managed manufacturing lines in Germany and the United Kingdom. Nexperia China framed the milestone as a validation of its "independent R&D and mass production capabilities," marking the moment the subsidiary demonstrated it could design and produce advanced discrete semiconductors without European support .
The technical significance goes beyond symbolism. Most of Nexperia's legacy production outside China has relied on 8-inch wafers and smaller nodes. The move to 12-inch wafers inside China represents a leap in both capability and production volume, potentially allowing the Chinese unit to serve a broader set of global customers directly under its "China for China" and "China for global" strategy .
The push for independence cannot be separated from Wingtech's ongoing legal campaign to reclaim the Dutch parent company. In October 2025, the Dutch government invoked a rarely used Cold War-era law—the Goods Availability Act—to seize effective control of Nexperia BV, citing national security concerns and what it called "serious governance shortcomings" . An Amsterdam Enterprise Chamber ruling suspended Nexperia's CEO and placed nearly all voting rights attached to Wingtech's shares under the control of court-appointed administrators
.
Although the Dutch government suspended its direct intervention in November 2025, the Enterprise Chamber's measures remain in place, and Wingtech's voting authority over its own subsidiary is still blocked . Wingtech has responded by appealing to the Dutch Supreme Court, accusing the Chamber of overstepping its jurisdiction
.
The company has also pursued legal action in China, filing a lawsuit against Nexperia and accusing the Dutch unit of conspiring to create a non-Chinese supply chain to permanently sever Wingtech's ownership . These parallel court battles create the very operational risk that Wingtech's independent China strategy is designed to mitigate: even if European legal proceedings drag on for years, Nexperia China can continue manufacturing, signing customer contracts, and developing new products on its own.
The Nexperia split matters because the company is not a niche player. It is one of the world's largest manufacturers of essential chips used in cars, industrial equipment, and consumer electronics—components that are relatively low-tech but absolutely critical. A disruption in Nexperia's output can ripple through global automotive supply chains, which is precisely the concern that prompted the Dutch government's original intervention in 2025 .
The creation of an independent Nexperia China may accelerate a broader trend in which semiconductor supply chains fragment along geopolitical lines. What began as a dispute between Wingtech and Dutch regulators has already produced a de facto operational partition, with one entity serving primarily the Chinese market using Chinese suppliers and another entity serving European customers through a Nijmegen-managed network . If the legal impasse continues, the two operations are unlikely to merge back into a single structure anytime soon.
Comments
0 comments